Highlights Organon & Co.

Equities

OGN

US68622V1061

Market Closed - Nyse Other stock markets 04:00:02 2024-06-07 pm EDT			5-day change	1st Jan Change
20.75 ^USD	+0.39%		-2.72%	+43.90%

May. 24	Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation	MT
May. 24	Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications for Hlx14	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications for Hlx14	May. 24	CI
Organon Reports Pricing of $1 Billion Senior Notes Offering	May. 08	MT
Organon Plans Offerings of Secured, Unsecured Senior Notes Totaling $1 Billion	May. 07	MT
Organon's Q1 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance, Quarterly Dividend Maintained	May. 02	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q1 Revenue $1.62B, vs. Street Est of $1.56B	May. 02	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q1 EPS $1.22, vs. Street Est of $0.93	May. 02	MT
Organon & Co. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Organon & Co. Provides Earnings Guidance for the Year 2023	May. 02	CI
Organon & Co Declares Quarterly Dividend on Common Stock, Payable on June 13, 2024	May. 02	CI
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	Apr. 08	MT
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	Mar. 19	MT
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	Feb. 20	CI
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	Feb. 20	CI
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	Feb. 15	MT
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Earnings Flash (OGN) ORGANON & CO. Posts Q4 Revenue $1.6B, vs. Street Est of $1.48B	Feb. 15	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q4 EPS $0.88, vs. Street Est of $0.83	Feb. 15	MT
Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024	Feb. 15	CI
Organon & Co. Provides Earnings Guidance for the Year 2024	Feb. 15	CI
Organon?S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older	Jan. 10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Organon & Co.

Equities

OGN

US68622V1061

Highlights

Filters